Head-To-Head Comparison: IceCure Medical (NASDAQ:ICCM) vs. Neovasc (NASDAQ:NVCN)

Neovasc (NASDAQ:NVCN – Get Rating) and IceCure Medical (NASDAQ:ICCM – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Profitability

This table compares Neovasc and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neovasc	-1,077.37%	-78.98%	-56.59%
IceCure Medical	-462.46%	-77.00%	-61.72%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neovasc and IceCure Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neovasc	0	2	0	0	2.00
IceCure Medical	0	0	2	0	3.00

IceCure Medical has a consensus price target of $4.38, suggesting a potential upside of 285.46%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Neovasc.

Institutional and Insider Ownership

1.6% of Neovasc shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Neovasc has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500.

Earnings and Valuation

This table compares Neovasc and IceCure Medical’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neovasc	$2.55 million	31.43	-$24.89 million	($12.29)	-2.38
IceCure Medical	$4.14 million	12.51	-$9.90 million	($0.45)	-2.52

IceCure Medical has higher revenue and earnings than Neovasc. IceCure Medical is trading at a lower price-to-earnings ratio than Neovasc, indicating that it is currently the more affordable of the two stocks.

Summary

IceCure Medical beats Neovasc on 9 of the 14 factors compared between the two stocks.

About Neovasc

(Get Rating)

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

About IceCure Medical

(Get Rating)

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.